Xiaomi Stock Extends Slide on Nov 18: Worst‑Performing China Tech Name as Q3 Results Loom; HSBC Trims Target to HK$65.40
18 November 2025
3 mins read

Xiaomi Stock Extends Slide on Nov 18: Worst‑Performing China Tech Name as Q3 Results Loom; HSBC Trims Target to HK$65.40

HONG KONG — November 18, 2025 — Xiaomi Corp. (HKEX: 1810) fell again on Tuesday, capping a bruising few weeks that have turned the smartphone‑to‑EV group into the worst‑performing major Chinese tech stock heading into its third‑quarter earnings release this evening. A combination of margin pressure in handsets, questions around EV capacity and mix, and more cautious sell‑side targets continues to weigh on sentiment. 1

What moved today (Nov 18)

  • Intraday prints: A bearish block trade of 131,200 shares at HK$40.78 crossed at 10:50 a.m. HKT. At the time of the print, Xiaomi’s last price was down about 2.8% on the session; the day’s range to that point ran from HK$40.52 to HK$41.78, with turnover already over HK$4.1 billion on 100.76 million shares. (Intraday figures are time‑stamped and subject to change.) 2
  • Earnings clock: Xiaomi reports Q3 2025 after the close at 7:30 p.m. HKT. The company’s investor‑relations page confirms tonight’s timing for the results announcement. 3
  • Street setup: AASTOCKS’ broker roundup shows 15 houses projecting non‑IFRS adjusted net profit of RMB 9.51bn–10.56bn for Q3 (median ~RMB 10.07bn, +61% YoY). The note also flags Q3 global smartphone shipments ~45.3m and market expectations that EV deliveries topped 100,000 units in the quarter. Short‑selling activity today was notable, with a ~20% short‑selling ratio cited alongside real‑time quote data. 4

The bigger picture: Why Xiaomi slumped into the cellar

Fresh analysis today underscores how quickly the narrative flipped. After flirting with a US$200bn market value mid‑year, Xiaomi is now down nearly 30% from a September peak and ranks bottom on the Hang Seng Tech Index over that span. The pullback reflects rising memory‑chip costs (mobile DRAM contract prices +21% in October, with more increases likely), sluggish domestic consumption, and tougher iPhone 17 competition—all pressuring smartphone margins just as investors debate the pace and profitability of Xiaomi’s EV ramp. Short interest has drifted up toward 0.7% of free float, while the average price target has been trimmed >8% since August, even as mainland “southbound” buyers logged 13 straight days of net purchases through Friday. 1

What analysts are saying right now

  • HSBC: The bank maintains a Buy but cuts its target price to HK$65.40 (from HK$75.90). Its latest write‑up reiterates confidence in Xiaomi’s premiumization strategy and share‑price upside over the medium term, while noting that mix and margin dynamics—across both smartphones and EVs—will be key. HSBC also expected Xiaomi’s “17 series” to benefit from Singles’ Day demand following the September launch. 5
  • Consensus into results: As noted above, brokers clustered around ~RMB 10bn in Q3 adjusted profit. The focus is less on headline profit, and more on forward guidance around component‑cost pass‑through, smartphone gross margins, EV profitability timing, and production capacity for higher‑end trims. 4

Five things to watch in tonight’s Q3 print

  1. Smartphone margin vs. DRAM/NAND inflation. With memory costs spiking, watch Xiaomi’s commentary on pricing power and cost absorption across Redmi and Xiaomi‑branded devices. 1
  2. EV business mix and profitability. Investors want clarity on model mix (including higher‑margin variants) and the timeline to sustained profitability in autos as capacity ramps. 4
  3. China demand vs. iPhone 17 cycle. Any color on competitive dynamics and sell‑through in key domestic channels will be scrutinized. 1
  4. International expansion cadence. Management’s milestones for overseas retail expansion and eventual EV exports will help frame 2026–2027 expectations. (Background: company plans communicated earlier this year.) 6
  5. Capital allocation and liquidity. After strong YTD volatility and earlier capital‑markets activity tied to the EV ramp, investors will parse cash, R&D outlays, and any buyback/dividend hints. (Background context.) 7

Key intraday stats (Nov 18, Hong Kong)

  • Large print: Bearish block of 131.2k shares @ HK$40.78 at 10:50 a.m. (indicative of ongoing supply).
  • Range/flow at that time:HK$41.78 / HK$40.52 range; ~100.8m shares traded; ~HK$4.12bn turnover.
  • Short‑selling tone:~20% short‑selling ratio cited in today’s market wrap.
    All figures above are intraday snapshots and may have changed by the close. 2

Bottom line

Xiaomi’s setup into Q3 is finely balanced: Street models still expect solid YoY profit growth, yet near‑term headwinds—cost inflation in memory, an aggressive iPhone cycle, and debates around EV mix/scale—have pushed the stock to the back of the China tech pack. Tonight’s update needs to reset expectations credibly on margins and EV profitability to stabilize the share‑price trajectory. 1


Disclosures & sources: This article synthesizes same‑day developments and third‑party reporting/market data from Moneyweb/Bloomberg, AASTOCKS, Xiaomi IR, and TradingView. Intraday prices and volumes are cited with timestamps and may differ at the close. 1

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Vanguard’s Crypto U-Turn: $10T Giant Opens Doors to Bitcoin ETFs
Previous Story

Bitcoin Price Today, 18 November 2025: BTC Slides Under $90,000 Before Rebounding Near $91K as ‘Extreme Fear’ Grips Crypto Market

Lloyds Share Price: Can the FTSE‑100 Bank’s Value Keep Surging or Is a Crash Coming?
Next Story

Lloyds Share Price Today, 18 November 2025: LLOY Drops 2% as BoE Ring‑Fencing and Curve Deal Stir Investor Jitters

Go toTop